JP2007535930A5 - - Google Patents

Download PDF

Info

Publication number
JP2007535930A5
JP2007535930A5 JP2007511437A JP2007511437A JP2007535930A5 JP 2007535930 A5 JP2007535930 A5 JP 2007535930A5 JP 2007511437 A JP2007511437 A JP 2007511437A JP 2007511437 A JP2007511437 A JP 2007511437A JP 2007535930 A5 JP2007535930 A5 JP 2007535930A5
Authority
JP
Japan
Prior art keywords
skin
subject
expression
antagonist
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007511437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535930A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/014720 external-priority patent/WO2005108616A1/en
Publication of JP2007535930A publication Critical patent/JP2007535930A/ja
Publication of JP2007535930A5 publication Critical patent/JP2007535930A5/ja
Pending legal-status Critical Current

Links

JP2007511437A 2004-05-03 2005-05-02 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法 Pending JP2007535930A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56774704P 2004-05-03 2004-05-03
PCT/US2005/014720 WO2005108616A1 (en) 2004-05-03 2005-05-02 Use of il-17 expression to predict skin inflammation; methods of treatment

Publications (2)

Publication Number Publication Date
JP2007535930A JP2007535930A (ja) 2007-12-13
JP2007535930A5 true JP2007535930A5 (enExample) 2008-06-19

Family

ID=34967584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007511437A Pending JP2007535930A (ja) 2004-05-03 2005-05-02 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法

Country Status (11)

Country Link
US (2) US7501247B2 (enExample)
EP (1) EP1761643A1 (enExample)
JP (1) JP2007535930A (enExample)
CN (1) CN1993480A (enExample)
AU (1) AU2005241020B2 (enExample)
BR (1) BRPI0510617A (enExample)
CA (1) CA2565566A1 (enExample)
MX (1) MXPA06012754A (enExample)
NO (1) NO20065560L (enExample)
WO (1) WO2005108616A1 (enExample)
ZA (1) ZA200609140B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK1576011T3 (da) 2002-10-30 2009-11-30 Genentech Inc Inhibering af IL-17 produktion
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US7704503B2 (en) * 2005-02-14 2010-04-27 Wyeth Llc Use of IL-17F in diagnosis and therapy of airway inflammation
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
CN101296706B (zh) * 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
AU2006330411B2 (en) 2005-12-29 2012-07-12 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, methods and uses
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
AU2007261019A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
US7846443B2 (en) 2006-08-11 2010-12-07 Schering Corporation Antibodies to IL-17A
EP2417974A1 (en) * 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN108451968A (zh) * 2009-04-15 2018-08-28 西北大学 寡核苷酸功能化的纳米颗粒的递送
PE20120815A1 (es) 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
AU2010313304B2 (en) 2009-10-30 2015-08-20 Janssen Biotech, Inc. IL-17A antagonists
WO2012061448A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
JP6279467B2 (ja) * 2011-06-27 2018-02-14 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡についての新規ｔｈ１７分化マーカーおよびその使用
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US11078265B2 (en) 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
CN104884473B (zh) 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
BR112017014684A2 (en) 2015-02-04 2018-01-09 Boehringer Ingelheim International Gmbh methods of treatment of inflammatory diseases
JP2018521047A (ja) * 2015-07-16 2018-08-02 イーライ リリー アンド カンパニー 掻痒の治療
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
AU2019266226A1 (en) 2018-05-09 2020-12-03 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4596046A3 (en) 2020-05-21 2025-10-22 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046420A2 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
NZ508878A (en) * 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
EP1287130B2 (en) * 2000-05-10 2017-07-26 Merck Sharp & Dohme Corp. Mammalian cytokine receptor subunit proteins, related reagents and methods
AU2002326285A1 (en) * 2001-01-25 2003-01-02 Zymogenetics, Inc. Method for treating psoriasis by using an il-17d antagonist
CA2442134A1 (en) * 2001-03-29 2002-10-10 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
DK1576011T3 (da) * 2002-10-30 2009-11-30 Genentech Inc Inhibering af IL-17 produktion
WO2004058178A2 (en) * 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
DE60336930D1 (de) 2002-12-31 2011-06-09 Schering Corp IL-27 et IL-2 pour le traitement du cancer
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7183057B2 (en) 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento

Similar Documents

Publication Publication Date Title
JP2007535930A5 (enExample)
Schierwagen et al. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis
Eardley et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease
Parikh et al. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis
Greenberg et al. Plasma biomarkers of tubular injury and inflammation are associated with CKD progression in children
Jarrar et al. Adipokines and cytokines in non‐alcoholic fatty liver disease
Michael et al. Epidemiology of anxiety disorders
Zhuo et al. Evaluation of renal biopsies in type 2 diabetic patients with kidney disease: a clinicopathological study of 216 cases
Bell et al. Assessment of cell‐cycle arrest biomarkers to predict early and delayed acute kidney injury
Zhang et al. Predictive value of ionized calcium in critically ill patients: an analysis of a large clinical database MIMIC II
Plastiras et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline
Hwang et al. Tissue expression of tubular injury markers is associated with renal function decline in diabetic nephropathy
JP2013231045A5 (enExample)
Bertrand et al. Elevated IL-3 and IL-12p40 levels in the lower airway of infants with RSV-induced bronchiolitis correlate with recurrent wheezing
Zhou et al. Urinary uromodulin excretion predicts progression of chronic kidney disease resulting from IgA nephropathy
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
Kim et al. Non-eosinophilic nasal polyps shows increased epithelial proliferation and localized disease pattern in the early stage
Park et al. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy
von Groote et al. Proenkephalin A 119–159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial
Iwasa et al. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study
Yagmur et al. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4
JP2013500941A5 (enExample)
JP2013060443A5 (enExample)
US20170328914A1 (en) Biomarkers of fast progression of chronic kidney disease
Fu et al. Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus